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Abstract The display of proteins or peptides on the surface of 
filamentous phages or phagemids has been shown to be a very 
powerful technology for the rescue of specific binders from large 
combinatorial libraries, as well as to select derivatives of known 
proteins with altered binding properties. The Bacillus thurin-
giensis (Bt) crystal proteins are a large family of insecticidal 
toxins which bind to receptors found on the brush border of larval 
midgut cells, different crystal toxins having different larval 
specificities. Here we describe the display of different CrylA(a) 
toxin regions on the surface of phagemids using the display 
vector pHENl, the purpose being the identification of toxin 
sequences suitable for mutagenesis and selection using phage 
display. We show that CrylA(a) domain II, in which the receptor 
binding activity is located, is efficiently displayed as well as being 
secreted as soluble protein into the periplasm of bacterial cell. 
This forms the basis of a simple means for the modification of 
toxin specificity and the selection of toxin proteins with novel or 
expanded host ranges. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Different isolates of soil Bacillus thuringiensis produce para-
sporal crystals. These crystals are composed of 8-endotoxins 
which are toxic to some insect pests and disease vectors. To 
date more than 50 different cry genes have been sequenced 
and reported. The sequence homology of different cry genes 
and analysis of the X-ray structure of Cry III A [1] and 
CrylA(a) [2] has revealed certain common features. Each con-
sists of three distinct domains. Domain I spans amino acid 
residues 1-290 and is believed to play an important role in the 
formation of the pore in the target cell membrane, this being 
considered to cause the toxicity of the protein. Hypervariable 
domain II, spanning amino acid residues 291-500 has been 
implicated in binding to the insect cell surface and can be 
considered to encode the receptor binding part of the toxin. 
Domain III, from residues 501 to C-terminus, has been specu-
lated to play a role in toxin stability and toxin integrity. Thus, 
interaction of domain II with the mid-gut receptor is consid-
ered one of the key factors for insect toxicity and specificity. 
Cry proteins which do not have measurable receptor binding 
activity are usually not toxic. Shuffling/swapping of domain II 
among different genes has resulted in alteration of insect sus-
ceptibility profile in a predictable fashion [3,4]. Similarly, 
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point mutations in the domain II can lead to the loss of 
toxicity, towards target pests. 
Geometrically, domain II displays three surface exposed 
loops. Of these, residues RRPFNIGI within loop 2 have 
been postulated to play an important role in the molecular 
recognition process of toxin-receptor interaction [5]. In addi-
tion to the identification of critical amino acids involved in 
receptor recognition in domain II, cc5 segment of domain I 
has also been evaluated for pore formation ability [6]. These 
observations raise the possibility that local amino acid substi-
tutions or mutations within the critical regions of domain II 
may be a means to increase toxin host range and potency. We 
believe peptides of domain II and I could be exploited to 
simulate the interaction of the toxin with its receptor on the 
susceptible insect cell surface and the subsequent toxicity. 
Recently, filamentous bacteriophages have been used to dis-
play peptides and proteins fused to the minor g3p or major 
g8p coat proteins [7,8]. Libraries of mutant or variant proteins 
can be cloned into phage proteins (usually g3p or g8p) by a 
number of different mutagenesis techniques. After rounds of 
selection, each of which involves the binding of phages to an 
appropriate ligand, elution and amplification, variants of the 
original protein can be derived on the basis of modified bind-
ing activity. Two vector systems have been used for the crea-
tion of such libraries. Phagemids are plasmids which contain a 
phage origin of replication as well as either gene III or gene 
VIII which are modified to allow the insertion of exogenous 
sequences [9]. These require the use of helper phages (which 
supply all the others phage proteins necessary to make func-
tional phage) to rescue the fusion protein which is incorpo-
rated into phage particle along with the helper phage g3p. In 
phage vectors, gene III or VIII is directly modified by the 
insertion of the exogenous sequences and are functional in 
the absence of helper phages. In the phagemid pHENl a 
myc tag and an amber stop codon are present at the 5' end 
of gene III. The amber mutation allows the secretion of the 
cloned polypeptide in addition to its display, while myc tag is 
recognized by monoclonal antibody (mAb) 9E10 [10]. Here we 
describe the cloning of different CrylA(a) toxin fragments into 
the pHENl phagemid vector and report the expression of the 
fusion proteins on the phage coat. The final goal is to obtain a 
phagemid library expressing different toxin specificities which 
can be selected on receptors of resistant insect species. 
2. Materials and methods 
2.1. PCR and cloning 
The fusion proteins between fragments of CrylA(a) protein and 
glutathione S-transferase (GST) or gene III were constructed by 
PCR using a pBluescript KS+ (Stratagene) plasmid containing a 
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cloned Bt Cry I A (a) gene as template or by PCR assembly of oligo-
nucleotides. The following primers were used: 
Btl 5'-AGGCTGCAGGCTAGGAACCAAGCCATTTC-3' 
Bt2 5'-CGGCTCGAGAAAAATCCCCAAACCAGTTA-3' 
Bt3 5'-GGTCTCGAGATACGTTGGATAGCACTCAT-3' 
Btl2-1 5'-CGCGGATCCTGCAGGAr7M7M^GJ4rG,4,4AGAA-
GAATTATACTTGGT-3' 
Btl2-2 5'-CCGGAATTCTCGAGTTCCTGATTATTTGGGCCT-
GAACCAAGTATAA-3' 
BtDII-1 5'-CGCGGATCCTGCAGTTTGATGGTAGTTTTCGTG-
GA-3' 
BtDII-2 5'-CCGGAATTCTCGAGACTGCGATGCTGCCAA-
GAAA-3' 
Enzyme restriction sites are underlined; the primer Btl contains a 
Pstl site; the primers Bt2 and Bt3 contain an Xhol site; two over-
lapping sites were inserted in the remaining primers: BamHI and Pstl 
in Btl2-1 and BtDII-1 and EcoRI and Xhol in Btl2-2 and BtDII-2. 
Bold sequences correspond to Bt CrylA(a) gene. The primer Btll 
contains the sequence for FLAG tag sequence (in italic). Three frag-
ments of CrylA(a) gene overlapping regions were amplified by PCR 
(Fig. 1) The fragments coding amino acids 92-358 (BtS - short frag-
ment) and amino acids 92-732 (BtL - large fragment) of the native 
protoxin were amplified using Btl as sense primer and Bt2 and Bt3 as 
reverse primers, respectively. The fragment encoding domain II 
(BtDII, amino acids 276^158) was amplified with BtDII-1 as sense 
and BtDII-2 as reverse primer. The PCR conditions were: 30 cycles 
of 94°C 1 min, 55°C 1 min, 72°C, 2 min. The primary PCR amplifi-
cation products were gel purified and digested with Pstl and Xhol to 
subclone in pHENl phagemid vector. The resulted vectors were 
named pHENl-BtL, pHENl-BtS and pHENl-BtDII. The amplified 
fragment BtDII was digested with BamHI and EcoRI; since the do-
main II sequence contains an EcoRI site the digestion generated two 
fragments; these were consecutively cloned in the pGEX-3X vector 
(Pharmacia Biotech) to obtain the vector pGEX-BtDII. 
To generate fragment Btl2 coding for amino acids from 367 to 379, 
a PCR with overlapping oligonucleotides Btl2-1 and Btl2-2 was per-
formed without template. PCR conditions were: 40 cycles of 94°C 1 
min, 50°C 1 min, 72°C 2 min. The PCR product of the correct di-
mension was gel purified and digested with Pstl and Xhol to subclone 
in pHENl phagemid vector, and with BamHI and .EcoRI to subclone 
in the pGEX-3X vector. The subsequent vectors were named p H E N l -
Btl2 and pGEX-Btl2, respectively. Following purification, aliquots of 
all recombined vectors were used to transform E. coli DH5ocF'. In-
dividual colonies were screened for correct plasmid insertion by PCR 
and by DNA restriction analysis. 
2.2. Phage preparation 
To 1 ml of phagemid bearing bacteria (OD550 0.5) 1012 pfu (plaque 
forming units) Ml3 K07 helper phage were added. After 30 min in-
cubation at 37°C the bacteria were centrifuged and resuspended in 
Luria Bertani (LB) medium containing 100 ug/ml ampicillin and 20 
ug/ml kanamicin. After an overnight growth, phages were prepared 
from supernatant by two 20% PEG (20% polyethylene glycol 6000, 2.5 
M NaCl) precipitation. The phage pellet was resuspended in a volume 
of distilled water, 1:100 of the original culture volume. Phage titre 
was determined by making serial dilutions of phage suspension and 
adding 1 ml of DH5aF' bacteria (OD550 0.5). Drops of 5 ul of serially 
diluted bacterial suspension were plated on LB ampicillin-containing 
medium. After an overnight growth the number of ampicillin-resistant 
colonies was counted. 
2.3. Defective helper phage 
In one experiment the non-infectious mutant phage fKN16 was 
used. fkN16 carries a deletion removing the amino acids 29-197 of 
g3p [11]. DH5ocF' cells bearing fKN16 were transformed with phage-
mid DNA and selected on solid medium containing ampicillin. Phage 
particles were collected from supernatant as described above. 
2.4. pGEX-BtD2 and pGEX-Btl2 expression 
The vectors pGEX-BtDII and pGEX-Btl2 were used to express 
fusion protein GST-BtDII and GST-Btl2 in E. coli. After transfor-
mation, clones were screened by PCR and the correct orientation was 
checked by expression of the fusion protein. Positive clones were 
grown and after induction with 1 mM IPTG for 3 h, bacteria were 
pelleted and lysed. The fusion proteins were purified by binding to 
glutathione-agarose (GS4B, Pharmacia) and elution with reduced 15 
mM glutathione according to manufacturer's instructions. Finally, 
total cell lysates and soluble fusion proteins bound to glutathione-
agarose were analyzed by SDS PAGE. 
2.5. Preparation of rabbit antiserum to GST-Btl2 and affinity 
purification of antibodies 
One rabbit was injected with 300 mg of purified bacterial GST-Btl2 
fusion protein mixed 1:1 with complete Freund's adjuvant. This was 
followed by two booster shots of the same amount of protein in 
incomplete adjuvant. Immune serum (2 ml), after preclearing on 
GST column, was affinity purified by binding to Affi-Prep 10 support 
(Bio-Rad Laboratories) coupled to 1 mg of fusion protein, according 
to manufacturer's instructions. 
2.6. SDS-PAGE and Western blot analysis 
Sodium dodecyl sulfate (SDS) electrophoresis was performed ac-
cording to standard techniques. 1012 cfu (colony forming units) 
phagemids were denatured in boiling loading buffer, separated by 
polyacrylamide gel electrophoresis and transferred onto nitrocellulose 
(Amersham) by semi-dry blotting using the Pharmacia Multiphor II. 
The membrane was blocked using 5%i skimmed milk in PBS (MPBS) 
for 1 h at room temperature. A mAb to g3p [12], a mAb to myc tag or 
rabbit antibodies to GST-Btl2 were used as primary antibody. Mye-
loma culture supernatants containing the mAbs were diluted 1:5 in 
MPBS, purified anti-GST-Btl2 antibodies were diluted 1 ug/ml in 
MPBS and added to the blotted nitrocellulose sheets. After an over-
night incubation at 4°C and extensive washing with PBS plus 0.05% 
Tween 20, the nitrocellulose was subsequently incubated with anti-
mouse IgG goat antibodies conjugated with alkaline phosphatase or 
peroxidase (Dako), or anti-rabbit IgG goat antibodies conjugated 
with peroxidase (Dako). The positive bands were revealed by the 
chromogenic substrate BCIP (5-bromo-4-chloro-3-indolyl-phosphate) 
and NBT (nitro blue tetrazolium) (for alkaline phosphatase) or chemi-
luminescent ECL (Amersham) system (peroxidase). In one case a 
mAb Ml (Kodak) anti-FLAG was used as primary antibody accord-
ing to the protocol in [13]. 
3. Results 
3.1. Cloning strategy 
The cloning strategy is reported in Fig. 1. We have cloned 
four different CrylA(a) regions corresponding to almost the 
entire activated toxin, reported here as BtL, the N-terminal 
domain (BtS), the domain II (BtDII) and the second loop 
found in domain II R R I I L G S G P N N Q E (Btl2). 
3.2. Cloning and expression of BtL and BtS 
BtL and BtS sequences were obtained by P C R amplification 
of CrylA(a) cloned genes. After cloning into p H E N l , indi-
vidual colonies were grown in liquid medium and infected 
with M13K07 helper phage. Following infection, bacteria 
bearing p H E N l BtL lysed within 30 min while BtS showed 
slower growth than controls. p H E N l - B t L bacteria titrated 
before and after phage infection showed a loss of viability 
of around 90%. N o induced mortality was registered in 
p H E N l - B t S cells. After overnight growth, phagemids were 
recovered from the supernatant by P E G precipitation and 
titrated. The titres of the phage produced by viable 
p H E N l - B t L bacteria and p H E N l - B t S were always consider-
ably less than p H E N l controls (Table 1). In Western blots, no 
band with a molecular weight higher than g3p was recognized 
by the anti-g3p m A b (not shown). Considering the possible 
toxic effect of the recombinant g3p, infected bacteria were 
grown in presence of 1% glucose to reduce the expression of 
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Fig. 1. Schematic drawing of the cloning of different CrylA(a) toxin regions. Reference numbers of the amino acid residues at the ends of the 
cloned sequences are shown. The vertical bars in domain II represent three structural loops. 
the cloned toxin (glucose reduces the activity of the lac pro-
moter controlling expression of the displayed protein g3p fu-
sion). Bacteria grown under these conditions gave a slightly 
higher phage titre (Table 1), and Western blot of 1012 phages 
grown under these conditions showed a faint band with an 
apparent molecular weight of 90 kDa corresponding to the 
expected size of the fusion protein as well as a strong band of 
70 kDa corresponding either to the helper phage g3p or par-
tially degraded recombinant g3p (Fig. 2, lane 2, arrows B and 
A, respectively). In Fig. 2, lane 1, a reference pHENl phage is 
reported. Growth in glucose did not improve the display of 
BtL. To further improve the incorporation of the recombinant 
protein, a defective helper phage, fKN16, was used. This 
phage has a deletion in gene III and is non-infectious unless 
it incorporates g3p provided by a source in trans. In a pre-
vious experiment we found that fKN16 acts as helper phage 
utilizing preferentially the recombinant g3p instead of its par-
tially deleted g3p. DH5ccF' bacterial cells harbouring fKN16 
were transformed with pHENl-BtL phagemid DNA and, 
after growth, phages were recovered from the supernatant. 
The phage titre is reported in Table 1 and the respective West-
ern blot of 1012 cfu in Fig. 2, lane 3. In this case, other than 
the low molecular weight g3p of fKN16 (arrow D), an abun-
dant band in the range of g3p (arrow A) and an additional 
band around 94 kDa (arrow C) are recognized. A similar 
pattern is revealed by the bacterial cells producing the phage-
mids (Fig. 2, lane 4). Our interpretation of these results is 
that the recombinant protein, with a nominal molecular 
weight of 150 kDa, is degraded to band C and from there 
to a protease resistant g3p core. The last is selectively incor-
porated by nascent phages resulting in a limited presence of 
fragment C on the phage surface. 
Table 1 
Titres of phages produced by bacteria harbouring phagemids recom-
bined with different CrylA(a) sequences 
Phagemid 
pHENl 
pHENl-BtS 
pHENl-BtL 
pHENl-BtS 
pHENl-BtL 
pHENl-BtL 
pHENl-Btl2 
pHENl-BtDII 
Helper phage 
Ml 3 K07 
M13 K07 
M13 K07 
M13 K07 
Ml 3 K07 
fKN16 
M13 K07 
M13 K07 
Medium 
LB 
LB 
LB 
LB+1% Glu 
LB+1% Glu 
LB 
LB 
LB 
cfu/ml of culture 
1013 
5*109 
5*108 
1010 
109 
1012 
1013 
1013 
3.3. Cloning and expression of BtDII and Btl2 
Loop 2 RRIILGSGPNNQE fragment was obtained by 
PCR assembly of two oligonucleotides comprising the coding 
sequence, the restriction sites for the insertion in pHENl and 
pGEX and the coding sequence for the FLAG epitope 
DYKDE recognized by the mAb Ml. This tag was inserted 
at the N-terminus to facilitate the recognition of the loop 2 
peptide on g3p. DII fragment was obtained directly by PCR 
amplification of CrylA(a) cloned gene. After transformation 
the positive clones were identified by PCR. The titres of the 
resulting pHENl-Btl2 and pHENl-BtDII phages, reported in 
Table 1, are similar to those of the control pHENl phage, 
indicating that these constructs are far less toxic than 
pHENl-BtS and pHENl BtL phagemids. In Western blot-
ting using the mAb anti-g3p, 1012 cfu of pHENl-BtDII 
phages (Fig. 3, lane 3) show a doublet of 85/90 kDa (arrow 
A) in addition to a g3p sized band. 90 kDa is the size expected 
for full-length domain II attached to g3p, indicating that this 
domain is well displayed. The smaller 85 kDa band probably 
represents a degradation product which has lost approxi-
mately 50 amino acids at the N-terminus. The g3p band is a 
doublet, probably due to the difference in molecular weight 
between the g3p of the helper phage and the g3p of pHENl 
which has an additional polylinker and a myc tag sequence. 
According to this interpretation, the double g3p band present 
in pHENl-BtDII attests a partial degradation of the fusion 
protein. As far as the pHENl Btl2 is concerned, no evidence 
of expression can be inferred by Western blot (Fig. 3, lane 2) 
because the reduced dimension of the peptide. Unfortunately, 
no recognition occurred using the anti-FLAG mAb. We hy-
pothesize that the mAb failure in tag recognition could be 
caused by the toxin amino acids positioned downstream. It 
has been demonstrated that the type of the amino acid follow-
ing the FLAG peptide disturbs the mAb reactivity [14]. To 
confirm the expression of the cloned peptide on the phagemid 
particles, a Western blot using a rabbit antiserum raised to 
GST-Btl2 fusion protein (see below) was performed. The re-
sults are reported in Fig. 3. If compared to the pHENl con-
trol (lane 4) the pHENl-Btl2 phages show a strong positive 
band (lane 5) corresponding to the fusion protein Btl2-g3p. 
The ability of pHENl-BtDII phages to direct the secretion 
of domain II fragment was investigated in a non-suppressor 
E. coli strain (HB2151). In these bacteria the amber codon is 
read as a stop codon causing the release of the cloned protein 
into the periplasmic space. The Western blot of the periplas-
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Fig. 2. Western blots of phages displaying CrylA(a) toxin frag-
ments. Lane 1: control pHENl; lane 2: pHENl-BtS; lane 3: 
pHENl-BtL (fKN16 helper phage), lane 4: protein extract of bacte-
rial cells harbouring pHENl-BtL and fKN16. Lanes 1 and 2: anti-
g3p monoclonal antibody; secondary antibody: alkaline phospha-
tase-conjugated goat anti-mouse antibodies; substrates: BCIP and 
NBT. Lanes 3 and 4: mAb anti-g3p; secondary antibody: peroxi-
dase-conjugated goat anti-mouse antibodies. Substrate: ECL. Arrow 
A: g3p; arrow B: BtS-g3p fusion protein; arrow C: proteolitic 
fragment of BtL-g3p; arrow D: fKN16 deleted g3p. 
mic space of HB2151 E. coli infected with pHENl-BtDII 
phages is shown in Fig. 3, lane 7. The BtDII band identified 
by mAb 9E10 recognizing the myc tag at the C-terminus has 
an apparent molecular weight of around 25 kDa, correspond-
ing to that expected for the size of domain II. In lane 6 
pHENl phagemids are reported for reference. 
3.4. Cloning and expression in pGEX 
BtDII and Btl2 sequences were cloned in pGEX which will 
express the cloned gene as a protein fused to glutathione S-
transferase. The purpose of the cloning was to study the ex-
pression of the toxin fragment in another fusion system and 
provide purified toxin antigens for the production of specific 
antisera. After cloning, bacterial cell lysates were purified by 
affinity chromatography and the eluted fractions analyzed by 
SDS-PAGE. In Fig. 4 the cell lysate (lane 1), the purified 
GST-BtDII (lane 2) and GST-Btl2 (lane 3) are reported. 
The mobility of GST-BtDII polypeptides corresponds to 
that expected for the predicted molecular weight of the fusion 
product. The GST-Btl2 band has a mobility slightly lesser 
than the GST polypeptide alone (lane 4) attesting the expres-
sion of the Btl2 peptide. The polypeptides bands are clean and 
without degradation products. Purified GST-Btl2 was used to 
obtain the rabbit antiserum mentioned above. 
4. Discussion 
To date many different molecules have been used for phage 
display, including antibody fragments, enzymes, and hor-
mones [15]. The possibility of using phage display to isolate 
a polypeptide with binding characteristics which differ from 
the original protein depends on the level of expression and 
stability of the displayed molecule. Here we have displayed 
different parts of the CrylA(a) toxin in an attempt to under-
stand the form most suitable for display and subsequent mu-
tagenesis and selection. Cloning of a large fragment corre-
sponding to the activated toxin caused slowed bacterial 
growth, but did not cause lysis unless the bacteria were also 
infected with a helper phage. We feel that this may arise from 
the insertion of a functional toxin pore molecule into the cell 
membrane following phage extrusion. The induction of tox-
icity is probably responsible for the lack of display observed. 
Using the defective phage fKN16 we found that a low amount 
of the toxin could be incorporated, but the dimension of the 
polypeptide is far lower than the whole toxin and presumably 
lacking the N-terminal region where the lytic activity is lo-
cated. In a recent work [16] it is shown that mutations in 
conserved block 4 of domain III affect conductance of ion 
channels formed by the toxin. This finding may account for 
the high lysis with pHENl-BtL as compared to pHENl-BtS. 
A better result is obtained cloning loop 2 binding region and 
domain II sequences. Bacteria bearing respective recombinant 
phagemids showed no problems during growth and rescued 
phages had normal titres. Since the mAb anti-FLAG failed 
the epitope recognition, the expression of the loop 2 sequence 
MW 
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Fig. 3. Western blots of phages displaying CrylA(a) toxin fragments and soluble toxin. Lane 1: control pHENl; lane 2: pHENl-Btl2; lane 3: 
pHENl-BtDII; lane 4: control pHENl; lane 5: pHENl-Btl2; lane 6: control pHENl; lane 7: soluble BtDII. Lanes 1-3: mAb anti-g3p; sec-
ondary antibody: alkaline phosphatase-conjugated goat anti-mouse antibodies. Substrates: BCIP and NBT. Lanes 4 and 5: affinity purified rab-
bit antibodies anti Btl2; secondary antibody: peroxidase-conjugated goat anti-rabbit antibodies; substrate: ECL. Lanes 6 and 7: anti-myc tag 
monoclonal antibody; secondary antibody: peroxidase-conjugated goat anti-mouse antibodies. Substrate: ECL. Arrow A indicates BtDII-g3p 
fusion protein bands. 
R Marzari et allFEBS Letters 411 (1997) 27-31 31 
\ 1 U 
<H— 
67 — 
43 — 
30 — 
I 3 
Fig. 4. Coomassie Blue-stained SDS-PAGE of CrylA(a) toxin frag-
ments cloned in pGEX plasmid. Lane 1: bacterial extract; lane 2: 
affinity purified GST-BtDII; lane 3: purified GST-Btl2; lane 4: pu-
rified GST. 
on phages was confirmed by the antiserum specifically raised 
to the GST-Btl2 fusion protein. On the basis of Western blot 
band intensity, we estimate that domain II is displayed on 
approximately 5-10% of phagemids, a level comparable to 
those we see with other proteins, such as single chain antibody 
fragments (data not shown). The correct synthesis of domain 
II is confirmed by the purity of the soluble form secreted by 
non suppressor E. coli strain. Both Btl2 and BtDII yielded 
large amount of undegraded fusion proteins when cloned in 
pGEX vector which expresses these polypeptides fused to 
GST. 
In conclusion loop 2 and domain II appear promising for 
phage binding studies. In particular, for the creation of libra-
ries of mutants with changes in amino acids predicted to be 
important for binding to the target cell receptor. Such phage 
libraries could be panned to isolate new toxin specificities to 
resistant insect species on the basis of phage binding to mid-
gut vesicles, cultured cells [17] or cell receptors cloned and 
expressed as fusion protein on the surface of bacterial cells 
[18] or as purified proteins. 
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